RWM
HAE icon

Rialto Wealth Management’s Haemonetics HAE Stock Holding History

Rialto Wealth Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$450 Buy
6
+1
+20% +$64 ﹤0.01% 1764
2026
Q1 		$282 Buy
5
+1
+25% +$65 ﹤0.01% 1548
2025
Q4 		$321 Buy
+4
New +$269 ﹤0.01% 1413
2025
Q3 		– Sell
-3
Closed -$224 – 1746
2025
Q2 		$224 Buy
+3
New +$199 ﹤0.01% 1345

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rialto Wealth Management's HAE Position: Q2 2026 in Review

Rialto Wealth Management increased its Haemonetics (HAE) stake by 20% in Q2 2026, buying an estimated $64 and bringing the position to 6 shares worth $450. The position accounts for ﹤0.01% of the portfolio, ranked #1764.

Rialto Wealth Management first reported a position in HAE in Q2 2025 and has held it in 4 quarters since. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Rialto Wealth Management held 6 shares of Haemonetics worth $450 as of Q2 2026.
  • Rialto Wealth Management bought 1 Haemonetics share in Q2 2026, an estimated $64.
  • Haemonetics made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #1764 holding.
  • Rialto Wealth Management first reported a position in Haemonetics in Q2 2025 and has held it in 4 quarters since.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.